Related Experiment Video
Updated: Dec 27, 2025
06:16
Involving Individuals with Developmental Language Disorder and Their Parents/Carers in Research Priority Setting
Published on: June 6, 2020
4.2K
Filling gaps in type 1 diabetes and exercise research: a scoping review and priority-setting project
Nika M D Klaprat1,2, Nicole Askin3, Andrea MacIntosh4,2
1Diabetes Research Envisioned and Accomplished in Manitoba (DREAM) Theme, University of Manitoba, Children's Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada nklaprat@chrim.ca.
BMJ Open Diabetes Research & Care
|March 7, 2020
Summary
Patient engagement is missing in type 1 diabetes exercise research. Top priorities focus on lifestyle and exercise for glycemic control, but trials haven't incorporated patient perspectives or outcomes yet.
Area of Science:
- Endocrinology and Metabolism
- Exercise Science
- Clinical Trial Methodology
Background:
- Patient engagement (PE) is crucial for relevant research, yet its integration into type 1 diabetes (T1D) exercise trials is unclear.
- Existing T1D exercise research often lacks patient-reported outcomes (PROs) and patient perspectives.
Purpose of the Study:
- To assess PE practices in T1D exercise randomized trials.
- To identify and prioritize future exercise research needs from T1D stakeholders.
Main Methods:
- A scoping review of published and grey literature identified exercise trials in T1D.
- A modified James Lind Alliance approach, including an online survey and stakeholder committee, set research priorities.
- Studies were screened for PE and PROs; survey data were qualitatively analyzed.
Main Results:
- Nineteen trials and 4 registrations met criteria; none incorporated PE.
- Commonly measured PROs included hypoglycemia frequency and quality of life.
- 194 research questions were collected, leading to 10 priorities focused on lifestyle and exercise for glycemic control.
Conclusions:
- Current exercise trials for T1D lack patient engagement and comprehensive PROs.
- Identified research priorities emphasize lifestyle and exercise modifications for short-term glycemic control.
- Future clinical trials must incorporate patient-centered outcomes and engagement to address T1D research needs effectively.
Related Concept Videos
01:22Diabetes Mellitus: Overview and Type I Subtype
4.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.7K
01:22Diabetes Mellitus: Type 2 and Gestational
4.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.2K
01:15Diabetes: Management and Pharmacotherapy
786
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
786
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
338
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
338
01:16Insulin: Dosing Regimen and Adverse Effects
587
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
587